PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19387337-8 2009 Our data suggest that propranolol may prevent the development of PDAC by blocking cAMP-dependent intracellular signaling, cAMP-dependent release of epidermal growth factor, and PKA-dependent release of vascular endothelial growth factor while additionally downregulating the alpha7 nAChR by inhibiting cAMP-mediated subunit assembly. Propranolol 22-33 vascular endothelial growth factor A Homo sapiens 202-236 34721024-8 2021 In addition, propranolol or T1012G treatment induced a 35.06% +- 0.53% or 35.49% +- 2.68% reduction in VEGF secretion in HUVECs (p < 0.01/p < 0.01). Propranolol 13-24 vascular endothelial growth factor A Homo sapiens 103-107 34383343-1 2021 Retraction: "Propranolol suppresses HUVEC viability, migration, VEGF expression, and promotes apoptosis by downregulation of miR-4295", by Feng Zhao, Xiaoliang Yang, Guangqi Xu, Jianhai Bi, Renrong Lv, and Ran Huo, J Cell Biochem. Propranolol 13-24 vascular endothelial growth factor A Homo sapiens 64-68 34697590-0 2021 Propranolol Suppresses Proliferation and Migration of HUVECs through Regulation of the miR-206/VEGFA Axis. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 95-100 34697590-12 2021 Collectively, the findings of the present study demonstrated that propranolol may inhibit the proliferation and migration in HUVECs via modulating the miR-206/VEGFA axis. Propranolol 66-77 vascular endothelial growth factor A Homo sapiens 159-164 17079456-5 2006 Norepi treatment increased MMP-2, MMP-9, and VEGF levels in culture supernatants of HONE-1 cells, which could be inhibited by the beta-blocker propranolol. Propranolol 143-154 vascular endothelial growth factor A Homo sapiens 45-49 33776033-6 2021 Propranolol inhibited migration, network formation, vascular endothelial growth factor A production, and vascular endothelial growth factor receptor 2 activation and down-regulated PI3K/AKT and mitogen-activated protein kinase signaling in hemangioma endothelial cells, but it increased ERK1/2 activity in hemangioma stem cells. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 52-88 34721024-9 2021 Cotreatment further inhibited VEGF secretion compared with the monotherapies (compared with propranolol treatment: 75.06% +- 1.50% decrease, compared with T1012G treatment: 74.91% +- 0.68%; p<0.001, p < 0.001). Propranolol 92-103 vascular endothelial growth factor A Homo sapiens 30-34 34430434-0 2021 Propranolol inhibits infantile hemangioma by regulating the miR-424/vascular endothelial growth factor-A (VEGFA) axis. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 106-111 34477031-0 2022 Vascular endothelial growth factor response with propranolol therapy in patients with infantile hemangioma. Propranolol 49-60 vascular endothelial growth factor A Homo sapiens 0-34 34477031-8 2022 Propranolol therapy induced a significant decline in VEGF levels at the 3-month evaluation in patients in the proliferative phase; however, this did not reach the levels of IH in the involuting phase. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 53-57 34430434-10 2021 As the concentration of propranolol increased, XPTS-1 cell viability gradually decreased (P<0.05), and the expression level of VEGFA decreased (P<0.05). Propranolol 24-35 vascular endothelial growth factor A Homo sapiens 127-132 34430434-15 2021 Compared with the propranolol group, the XPTS-1 cell viability and invasion ability in the propranolol + VEGFA-si group were significantly decreased (P<0.05), while the level of apoptosis increased (P<0.05). Propranolol 18-29 vascular endothelial growth factor A Homo sapiens 105-110 34430434-15 2021 Compared with the propranolol group, the XPTS-1 cell viability and invasion ability in the propranolol + VEGFA-si group were significantly decreased (P<0.05), while the level of apoptosis increased (P<0.05). Propranolol 91-102 vascular endothelial growth factor A Homo sapiens 105-110 34430434-17 2021 Conclusions: Propranolol affects the malignant biological behavior of IHA cells by regulating the miR-424/VEGFA axis. Propranolol 13-24 vascular endothelial growth factor A Homo sapiens 106-111 33575332-8 2021 Conclusion: Propranolol can inhibit the proliferation, migration, invasion, adhesion, and tube formation of hemangioma endothelial cells; block VEGF-mediated angiogenesis signaling pathway; suppress the expressions of downstream angiogenesis-related signaling molecules; and ultimately achieve the effect of treatment of IHs. Propranolol 12-23 vascular endothelial growth factor A Homo sapiens 144-148 35240444-0 2022 Propranolol inhibits cell viability and expression of the pro-tumorigenic proteins Akt, NF-kB, and VEGF in oral squamous cell carcinoma. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 99-103 33715934-10 2021 Serum GLUT1, IGF-2, and VEGF-A levels in patients with hemangioma receiving propranolol treatment were significantly higher than in healthy controls. Propranolol 76-87 vascular endothelial growth factor A Homo sapiens 24-30 33715934-12 2021 CONCLUSION: Serum GLUT1, IGF-2, and VEGF-A levels were positively correlated with disease severity in patients with hemangioma, for example, in complicated hemangioma and hemangioma requiring propranolol treatment. Propranolol 192-203 vascular endothelial growth factor A Homo sapiens 36-42 33782804-9 2021 Propranolol also decreased the expression of phosphorylated CREB-ATF and MEK-ERK pathways; suppressed the expression of matrix metalloproteinase-2, 9 and vascular endothelial growth factor; and inhibited gastric cancer cell migration. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 154-188 32219146-1 2020 Objective: The aim of this study is to evaluate the association of genetic polymorphisms in Cytochrome P450 2D6(CYP2D6) and the change in VEGF levels with the response to propranolol in patients with Infantile hemangiomas (IH). Propranolol 171-182 vascular endothelial growth factor A Homo sapiens 138-142 32854260-6 2020 Propranolol and ICI-118,551 activated apoptosis inhibited gene and protein expression of HIF-2alpha, CAIX, and VEGF, and impaired partially the nuclear internalization of HIF-2alpha and NFkB/p65. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 111-115 32311699-9 2020 Patients with higher bFGF and VEGF levels showed better response to propranolol at 1 year. Propranolol 68-79 vascular endothelial growth factor A Homo sapiens 30-34 32311699-11 2020 Pretreatment bFGF and VEGF could be novel biomarkers for predicting response to propranolol. Propranolol 80-91 vascular endothelial growth factor A Homo sapiens 22-26 32311699-12 2020 IMPACT: We found that decreases in the concentrations of MMP-2, bFGF, VEGF, and MCP-1 were associated with regression of the hemangioma, which indicates that one of the mechanisms of propranolol in the treatment of proliferative hemangiomas may involve downregulation of those cytokines.Patients with higher bFGF and VEGF levels showed better response to propranolol at 1 year. Propranolol 183-194 vascular endothelial growth factor A Homo sapiens 70-74 32311699-12 2020 IMPACT: We found that decreases in the concentrations of MMP-2, bFGF, VEGF, and MCP-1 were associated with regression of the hemangioma, which indicates that one of the mechanisms of propranolol in the treatment of proliferative hemangiomas may involve downregulation of those cytokines.Patients with higher bFGF and VEGF levels showed better response to propranolol at 1 year. Propranolol 183-194 vascular endothelial growth factor A Homo sapiens 317-321 32139988-4 2020 In this study, we attempted to assess whether propranolol has any effect on vascular endothelial growth factor (VEGF) and tissue inhibitor of metalloproteinase-2 (TIMP-2) over a period of time, and if it is there, how long it affects it. Propranolol 46-57 vascular endothelial growth factor A Homo sapiens 76-110 32139988-4 2020 In this study, we attempted to assess whether propranolol has any effect on vascular endothelial growth factor (VEGF) and tissue inhibitor of metalloproteinase-2 (TIMP-2) over a period of time, and if it is there, how long it affects it. Propranolol 46-57 vascular endothelial growth factor A Homo sapiens 112-116 33372436-0 2020 Serum levels of VEGF and bFGF in infantile hemangiomas treated with propranolol. Propranolol 68-79 vascular endothelial growth factor A Homo sapiens 16-20 33372436-3 2020 METHODS: In this prospective study, we aimed to investigate the relationship between serum VEGF and bFGF levels and clinical characteristics and the serological changes in VEGF and bFGF levels associated with propranolol treatment in infants diagnosed with IH. Propranolol 209-220 vascular endothelial growth factor A Homo sapiens 172-176 26622443-0 2015 Clinical efficacy of propranolol in the treatment of hemangioma and changes in serum VEGF, bFGF and MMP-9. Propranolol 21-32 vascular endothelial growth factor A Homo sapiens 85-89 30368887-0 2019 Propranolol suppresses HUVEC viability, migration, VEGF expression, and promotes apoptosis by downregulation of miR-4295. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 51-55 30368887-11 2019 Meanwhile, the expressions of VEGF, VEGF-A, FLT1, FLT2, and FOXF1 were downregulated by propranolol exposure. Propranolol 88-99 vascular endothelial growth factor A Homo sapiens 30-34 30368887-11 2019 Meanwhile, the expressions of VEGF, VEGF-A, FLT1, FLT2, and FOXF1 were downregulated by propranolol exposure. Propranolol 88-99 vascular endothelial growth factor A Homo sapiens 36-42 30368887-14 2019 Propranolol suppressed HUVEC viability, migration, the expression of VEGF, VEGF-A, FLT1/2, FOXF1, and promoted apoptosis via downregulation of miR-4295. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 69-73 30368887-14 2019 Propranolol suppressed HUVEC viability, migration, the expression of VEGF, VEGF-A, FLT1/2, FOXF1, and promoted apoptosis via downregulation of miR-4295. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 75-81 30497198-8 2018 Similar to prior reports in infantile hemangiomas, propranolol induced apoptosis and paradoxically increased VEGF-A mRNA expression in patient-derived VHL-HBs and 786-O cells. Propranolol 51-62 vascular endothelial growth factor A Homo sapiens 109-115 29244114-3 2018 We speculated that propranolol, known to downregulate VEGF signalling, could be beneficial in patients with recurrent bleeding episodes and anaemia. Propranolol 19-30 vascular endothelial growth factor A Homo sapiens 54-58 29790692-4 2018 OBJECTIVES: The aim of the study was to assess serum concentrations of VEGF and bFGF in the course of propranolol therapy of IH in children, and to assess their clinical implications. Propranolol 102-113 vascular endothelial growth factor A Homo sapiens 71-75 29790692-13 2018 CONCLUSIONS: Serum concentrations of VEGF and bFGF decreased during the propranolol treatment of IH, which may indicate the effect of propranolol on both. Propranolol 72-83 vascular endothelial growth factor A Homo sapiens 37-41 29790692-13 2018 CONCLUSIONS: Serum concentrations of VEGF and bFGF decreased during the propranolol treatment of IH, which may indicate the effect of propranolol on both. Propranolol 134-145 vascular endothelial growth factor A Homo sapiens 37-41 29490757-8 2017 PNP-VEGFR was efficiently bound to human umbilical vein endothelial cells and human hemangioma endothelial cells in a VEGFR-dependent manner, resulting in enhanced cytotoxic effects and stronger inhibition of VEGF expression, compared to that of the untargeted propranolol-loaded nanoparticles (PNP) and propranolol. Propranolol 261-272 vascular endothelial growth factor A Homo sapiens 4-8 29490757-8 2017 PNP-VEGFR was efficiently bound to human umbilical vein endothelial cells and human hemangioma endothelial cells in a VEGFR-dependent manner, resulting in enhanced cytotoxic effects and stronger inhibition of VEGF expression, compared to that of the untargeted propranolol-loaded nanoparticles (PNP) and propranolol. Propranolol 304-315 vascular endothelial growth factor A Homo sapiens 4-8 26991797-0 2016 Propranolol for infantile hemangioma: Effect on plasma vascular endothelial growth factor. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 55-89 26991797-2 2016 The aim of this study was therefore to determine the efficacy of propranolol treatment and to evaluate changes in plasma VEGF in IH patients who underwent propranolol treatment. Propranolol 155-166 vascular endothelial growth factor A Homo sapiens 121-125 27178307-0 2016 Serum and tissue profile of VEGF and its receptors VGFR1/R2 in children with infantile hemangiomas on systemic propranolol treatment. Propranolol 111-122 vascular endothelial growth factor A Homo sapiens 28-32 27178307-4 2016 To investigate this claim, this study aims to analyze the serum and tissue profiles of VEGF and VEGRR1/2 in patients treated with propranolol. Propranolol 130-141 vascular endothelial growth factor A Homo sapiens 87-91 27178307-7 2016 Then we used immunohistochemistry to evaluate tissue expression of VEGF and VEGFR1/2 in IH treated (n=27) and not treated (n=45) with propranolol (II.). Propranolol 134-145 vascular endothelial growth factor A Homo sapiens 67-71 27178307-12 2016 (III) VEGF and VEGFR1 mRNA expression was significantly lower in IH tissue after propranolol treatment compared to those without treatment. Propranolol 81-92 vascular endothelial growth factor A Homo sapiens 6-10 26489635-0 2015 Effect of topical propranolol gel on plasma renin, angiotensin II and vascular endothelial growth factor in superficial infantile hemangiomas. Propranolol 18-29 vascular endothelial growth factor A Homo sapiens 70-104 26489635-1 2015 The effect of topical propranolol gel on the levels of plasma renin, angiotensin II (ATII) and vascular endothelial growth factor (VEGF) in superficial infantile hemangiomas (IHs) was investigated. Propranolol 22-33 vascular endothelial growth factor A Homo sapiens 95-129 26489635-1 2015 The effect of topical propranolol gel on the levels of plasma renin, angiotensin II (ATII) and vascular endothelial growth factor (VEGF) in superficial infantile hemangiomas (IHs) was investigated. Propranolol 22-33 vascular endothelial growth factor A Homo sapiens 131-135 31588689-8 2019 RESULTS: The results showed that propranolol exerts potent anti-proliferative effects, attenuates migration, reduces VEGF and induces cell cycle arrest and apoptosis in both UM and CM in a dose-dependent manner. Propranolol 33-44 vascular endothelial growth factor A Homo sapiens 117-121 31176001-8 2019 In vitro, catecholamine treatment triggered the M2 polarization of macrophages, enhanced the expression of VEGF, promoted tumor angiogenesis, and these catecholamine-stimulated effects could be reversed by the adrenergic receptor antagonist propranolol. Propranolol 241-252 vascular endothelial growth factor A Homo sapiens 107-111 30448832-7 2019 Propranolol also decreased the release of VEGF and LDH in the supernatant. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 42-46 30130526-12 2018 Besides, propranolol treatment blocked the DLL4/Notch1 and Akt signaling and inhibited VEGF expression in HemECs. Propranolol 9-20 vascular endothelial growth factor A Homo sapiens 87-91 29664206-0 2018 Pigment epithelium-derived factor/vascular endothelial growth factor ratio plays a crucial role in the spontaneous regression of infant hemangioma and in the therapeutic effect of propranolol. Propranolol 180-191 vascular endothelial growth factor A Homo sapiens 34-68 29664206-2 2018 Propranolol, the first-line therapy for IH, inhibits angiogenesis by downregulating activation of the vascular endothelial growth factor (VEGF) pathway, which is hyperactivated in IH. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 102-136 29664206-2 2018 Propranolol, the first-line therapy for IH, inhibits angiogenesis by downregulating activation of the vascular endothelial growth factor (VEGF) pathway, which is hyperactivated in IH. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 138-142 29664206-9 2018 Interestingly, we found that propranolol increased the PEDF/VEGF ratio but did so by lowering VEGF expression rather than by upregulating PEDF as expected. Propranolol 29-40 vascular endothelial growth factor A Homo sapiens 60-64 29664206-9 2018 Interestingly, we found that propranolol increased the PEDF/VEGF ratio but did so by lowering VEGF expression rather than by upregulating PEDF as expected. Propranolol 29-40 vascular endothelial growth factor A Homo sapiens 94-98 28087723-8 2017 RESULTS: Prophylactic propranolol in the prescribed dose of 1 mg/kg/day showed a decreasing trend in the incidence of ROP (56.8% vs 68.6%; p=0.39), need for laser therapy (21.56% vs 31.37%; p=0.37), treatment with anti-VEGF (3.92% vs 15.68%; p=0.09) or visual outcomes at 1 year in the study and control groups, respectively, though these reductions were not statistically significant. Propranolol 22-33 vascular endothelial growth factor A Homo sapiens 219-223 26489635-8 2015 Propranolol gel may suppress the proliferation of IHs by reducing VEGF. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 66-70 26622443-9 2015 The mechanism underlying the effects of propranolol may be associated with the downregulation of VEGF, bFGF and MMP-9 expression. Propranolol 40-51 vascular endothelial growth factor A Homo sapiens 97-101 25728347-11 2015 NO and VEGF release induced by norepinephrine was decreased by propranolol pretreatment, coincident with alterations in the phosphorylation of Akt, eNOS, and VEGFR-2. Propranolol 63-74 vascular endothelial growth factor A Homo sapiens 7-11 26238450-8 2015 Furthermore, the patient responded favorably and the disease was stabilized following treatment with the beta-blocking agent Propranolol alone which acts on VEGF-A alone, but not on soluble VEGF receptor-1 levels. Propranolol 125-136 vascular endothelial growth factor A Homo sapiens 157-163 26238450-10 2015 Furthermore, Propranolol acts on VEGF-A but not FLT1 expression. Propranolol 13-24 vascular endothelial growth factor A Homo sapiens 33-39 26238450-0 2015 The therapeutic response in Gorham"s syndrome to the beta-blocking agent propranolol is correlated to VEGF-A, but not to VEGF-C or FLT1 expression. Propranolol 73-84 vascular endothelial growth factor A Homo sapiens 102-108 25728347-0 2015 Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 96-100 25728347-10 2015 Propranolol inhibited norepinephrine-induced cell invasion by reducing the expression of MMP-9, VEGF, and p-cofilin. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 96-100 25728347-13 2015 CONCLUSIONS: The current study demonstrated the antiangiogenic properties of propranolol in vitro and that the drug was able to induce the regression of hemangioma cells via the inhibition of cell cycle progression, invasion, and tube formation, concomitantly with decreased NO and VEGF levels through the down-regulation of the PI3K/Akt/eNOS/VEGF pathway. Propranolol 77-88 vascular endothelial growth factor A Homo sapiens 282-286 25728347-13 2015 CONCLUSIONS: The current study demonstrated the antiangiogenic properties of propranolol in vitro and that the drug was able to induce the regression of hemangioma cells via the inhibition of cell cycle progression, invasion, and tube formation, concomitantly with decreased NO and VEGF levels through the down-regulation of the PI3K/Akt/eNOS/VEGF pathway. Propranolol 77-88 vascular endothelial growth factor A Homo sapiens 343-347 26665926-0 2015 [Effect of propranolol gel on plasma VEGF, bFGF and MMP-9 in proliferating infantile hemangiomas of superficial type]. Propranolol 11-22 vascular endothelial growth factor A Homo sapiens 37-41 26665926-1 2015 OBJECTIVE: To investigate the effect of topical propranolol gel on the levels of plasma vascular endothelial growth factor (VEGF), basic fibroblastic growth factor (bFGF) and matrix metalloproteinases-9 (MMP-9) in proliferating infantile hemangiomas (IHs) of superficial type. Propranolol 48-59 vascular endothelial growth factor A Homo sapiens 88-122 26665926-1 2015 OBJECTIVE: To investigate the effect of topical propranolol gel on the levels of plasma vascular endothelial growth factor (VEGF), basic fibroblastic growth factor (bFGF) and matrix metalloproteinases-9 (MMP-9) in proliferating infantile hemangiomas (IHs) of superficial type. Propranolol 48-59 vascular endothelial growth factor A Homo sapiens 124-128 26665926-11 2015 CONCLUSIONS: Propranolol gel may suppress the proliferation of superficial infantile bemangiomas by reducing VEGF and bFGF. Propranolol 13-24 vascular endothelial growth factor A Homo sapiens 109-113 25523517-2 2015 The efficacy of propranolol was related to the beta2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis. Propranolol 16-27 vascular endothelial growth factor A Homo sapiens 116-150 25523517-2 2015 The efficacy of propranolol was related to the beta2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis. Propranolol 16-27 vascular endothelial growth factor A Homo sapiens 152-156 25523517-2 2015 The efficacy of propranolol was related to the beta2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis. Propranolol 16-27 vascular endothelial growth factor A Homo sapiens 309-313 25523517-2 2015 The efficacy of propranolol was related to the beta2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis. Propranolol 190-201 vascular endothelial growth factor A Homo sapiens 116-150 25523517-2 2015 The efficacy of propranolol was related to the beta2-AR blockade and the consequent inhibition of the production of vascular endothelial growth factor (VEGF), suggesting the hypothesis that propranolol could also be effective in treating retinopathy of prematurity (ROP), a retinal pathology characterized by VEGF-induced neoangiogenesis. Propranolol 190-201 vascular endothelial growth factor A Homo sapiens 152-156 25490818-0 2014 [Expression of serum and urinary vascular endothelial growth factor-A and epidermal growth factor-like domain 7 in proliferating hemangioma treated with propranolol]. Propranolol 153-164 vascular endothelial growth factor A Homo sapiens 33-69 25490818-1 2014 OBJECTIVE: This study aims to investigate the expression levels of serum and urinary vascular endothelial growth factor-A (VEGF-A) and epidermal growth factor-like domain 7 (EGFL7) in proliferating infantile hemangioma patients under propranolol treatment. Propranolol 234-245 vascular endothelial growth factor A Homo sapiens 85-121 25490818-1 2014 OBJECTIVE: This study aims to investigate the expression levels of serum and urinary vascular endothelial growth factor-A (VEGF-A) and epidermal growth factor-like domain 7 (EGFL7) in proliferating infantile hemangioma patients under propranolol treatment. Propranolol 234-245 vascular endothelial growth factor A Homo sapiens 123-129 23291092-0 2013 Propranolol given orally for proliferating infantile haemangiomas: analysis of efficacy and serological changes in vascular endothelial growth factor and endothelial nitric oxide synthase in 35 patients. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 115-149 24933041-5 2014 In particular, the beta2-AR seems to be the mostly involved in these responses, and the beta1-/beta2-AR blocker propranolol results highly effective in inhibiting both the increase of VEGF expression caused by a hypoxic insult and the consequent neovascular response. Propranolol 112-123 vascular endothelial growth factor A Homo sapiens 184-188 25120757-10 2014 Propranolol down-regulated VEGF expression of hemSCs, instead of inducing apoptosis. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 27-31 25120757-12 2014 Therefore, our current results suggested propranolol could not induce apoptosis of hemSCs, but played a curative role though suppressing VEGF synthesis and enhancement of adipogenesis of hemSCs. Propranolol 41-52 vascular endothelial growth factor A Homo sapiens 137-141 24033364-10 2014 Moreover, HaemECs acquired greater resistance to propranolol treatment than HUVECs, whereas inhibition of VEGF/VEGFR-2 signalling in HaemECs sensitized these cells to propranolol-induced apoptosis. Propranolol 167-178 vascular endothelial growth factor A Homo sapiens 106-110 23909679-0 2013 Serum-level changes of vascular endothelial growth factor in children with infantile hemangioma after oral propranolol therapy. Propranolol 107-118 vascular endothelial growth factor A Homo sapiens 23-57 23909679-2 2013 The aim of this study was to evaluate the change in serum vascular endothelial growth factor (VEGF) levels in patients with IH who underwent propranolol treatment. Propranolol 141-152 vascular endothelial growth factor A Homo sapiens 58-92 23909679-2 2013 The aim of this study was to evaluate the change in serum vascular endothelial growth factor (VEGF) levels in patients with IH who underwent propranolol treatment. Propranolol 141-152 vascular endothelial growth factor A Homo sapiens 94-98 23909679-8 2013 Serum VEGF levels were higher in patients with IH and fell after 1 month of oral propranolol treatment. Propranolol 81-92 vascular endothelial growth factor A Homo sapiens 6-10 23217879-10 2012 Vascular endothelial growth factor (VEGF) expression was down-regulated by propranolol in a dose-dependent manner. Propranolol 75-86 vascular endothelial growth factor A Homo sapiens 0-34 23257321-3 2013 Our study aimed to assess the effect of propranolol on pediatric LM and the relationship between its effectiveness and vascular endothelial growth factor (VEGF) family members (VEGF-A, C and D). Propranolol 40-51 vascular endothelial growth factor A Homo sapiens 155-159 23217879-10 2012 Vascular endothelial growth factor (VEGF) expression was down-regulated by propranolol in a dose-dependent manner. Propranolol 75-86 vascular endothelial growth factor A Homo sapiens 36-40 22580939-0 2012 Propranolol induces regression of hemangioma cells through HIF-1alpha-mediated inhibition of VEGF-A. Propranolol 0-11 vascular endothelial growth factor A Homo sapiens 93-99 23092836-9 2012 CONCLUSIONS: Our results demonstrate that propranolol reduced HNSCC viability, induced apoptosis, and inhibited production of the proangiogenic protein VEGF. Propranolol 42-53 vascular endothelial growth factor A Homo sapiens 152-156 22580939-11 2012 CONCLUSIONS: Collectively, these data suggest that propranolol exerts its suppressive effects on hemangiomas through the HIF-1alpha-VEGF-A angiogenesis axis, with effects mediated through the PI3/Akt and p38/MAPK pathways. Propranolol 51-62 vascular endothelial growth factor A Homo sapiens 132-136 20715173-9 2011 In addition, pretreatment of cells with propranolol, a beta-adrenergic receptor (AR) blocker, completely abolished induction of VEGF expression and HIF-1alpha protein amount by NE in all of the tested cancer cells. Propranolol 40-51 vascular endothelial growth factor A Homo sapiens 128-132 22259987-2 2011 METHODS: The serum VEGF, MMP-9 was detected with ELISA assay before treatment and after 4 weeks and 8 weeks of propranolol treatment. Propranolol 111-122 vascular endothelial growth factor A Homo sapiens 19-23 22259987-7 2011 CONCLUSIONS: Propranolol can treat the proliferative hemangioma through decreasing the serum VEGF and MMP-9. Propranolol 13-24 vascular endothelial growth factor A Homo sapiens 93-97 19946348-8 2009 RESULTS: Propranolol significantly decreased VEGF production and also MMP-2 activity in PMA-activated human leukemic cell lines Molt-4, Jurkat and U937 at 30 microM concentration of the drug compared to untreated control cells (P<0.05). Propranolol 9-20 vascular endothelial growth factor A Homo sapiens 45-49 21042766-6 2010 Furthermore, propranolol decreased the level of NF-kappaB and then downregulated VEGF, Cox-2, MMP-2 and MMP-9 expression. Propranolol 13-24 vascular endothelial growth factor A Homo sapiens 81-85 21042766-7 2010 Collectively, these results suggested that propranolol repressed gastric cancer cell growth through the inhibition of beta-ARs and the downstream NF-kappaB-VEGF/MMP-2/9/COX-2 pathway. Propranolol 43-54 vascular endothelial growth factor A Homo sapiens 156-160 20732454-6 2010 Furthermore, inhibition by propranolol of vascular endothelial growth factor (VEGF)-induced tyrosine phosphorylation of VEGF receptor-2 lead to inhibition of downstream signaling such as the activation of the extracellular signal-regulated kinase-1/2 and the secretion of the extracellular matrix degrading enzyme MMP-2. Propranolol 27-38 vascular endothelial growth factor A Homo sapiens 42-76 20732454-6 2010 Furthermore, inhibition by propranolol of vascular endothelial growth factor (VEGF)-induced tyrosine phosphorylation of VEGF receptor-2 lead to inhibition of downstream signaling such as the activation of the extracellular signal-regulated kinase-1/2 and the secretion of the extracellular matrix degrading enzyme MMP-2. Propranolol 27-38 vascular endothelial growth factor A Homo sapiens 78-82 20732454-6 2010 Furthermore, inhibition by propranolol of vascular endothelial growth factor (VEGF)-induced tyrosine phosphorylation of VEGF receptor-2 lead to inhibition of downstream signaling such as the activation of the extracellular signal-regulated kinase-1/2 and the secretion of the extracellular matrix degrading enzyme MMP-2. Propranolol 27-38 vascular endothelial growth factor A Homo sapiens 120-124 20977754-9 2010 In addition, treatment with propranolol decreased the level of NF-kappaB and, subsequently, down-regulated VEGF, COX-2, and EGFR expression. Propranolol 28-39 vascular endothelial growth factor A Homo sapiens 107-111 20977754-10 2010 CONCLUSIONS: Taken together, these results suggested that propranolol enhanced the sensitivity of gastric cancer cells to radiation through the inhibition of beta-ARs and the downstream NF-kappaB-VEGF/EGFR/COX-2 pathway. Propranolol 58-69 vascular endothelial growth factor A Homo sapiens 196-200